While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

Disease-associated vision changes are common in GCA, with no significant difference in visual improvement observed with IV glucocorticoids vs oral therapy.

Presbyopia-correcting intraocular lenses have lower health care burden after bilateral cataract surgery relative to ...

An AI-powered platform can advance the processing speed of data from large multi-center clinical trials.

Investigators reviewed DNA methylation patterns and how they can aid in differential diagnoses for patients with lacrimal ...

The FDA has approved Epioxa™ HD 0.239% and Epioxa™ 0.177% for use in epithelium-on corneal collagen CXL for the treatment of ...

The study published in JAMA Ophthalmology – the first epidemiologic study to home in on eye injuries in pickleball – reviewed ...

Researchers assessed the quality of life measures of patients with thyroid eye disease treated with Veligrotug, a full antagonist humanized mAb to IGF-1R.

Investigators reviewed ocular side effects of semaglutide use from a global population-based study across 180 countries.

Explainable artificial intelligence (XAI) can identify clinically significant diabetic retinal neurodegeneration (DRN) on ...

Investigators conducted a large-scale retrospective cohort study of the prevalence and age of onset of retinal detachment and ...

Researchers compared the use of aflibercept 8 mg and 2 mg in patients with various retinal vein occlusion subtypes.